These are valid concerns and worth discussing openly with your care team. A few things to consider:
We don't frame insulin for T1D or SSRIs for depression as "dependency" — we frame them as treating chronic conditions. Obesity has a strong genetic and neurobiological basis, and framing pharmacotherapy as long-term management rather than a temporary fix is more consistent with the science.
That said, the pragmatic concerns about access and cost are very real and not trivial. The hope is that as generics and more competitors enter the market, access will improve. The FDA is also considering pathway guidance for GLP-1 RA biosimilars, which should eventually bring costs down significantly.
As for adolescent-specific concerns: there IS emerging data suggesting that treating obesity during adolescence may be more effective long-term than treating it in adulthood, because you're intervening before decades of adipocyte hyperplasia and metabolic set-point entrenchment. Whether that translates to better sustained outcomes post-discontinuation is an open research question.